Drug intelligence / Profile preview

Diabion GlucoShot

Development stage: Unknown
Lead developer: Generex Biotechnology
Modality: Small Molecules
Administration: Buccal

Overview

Diabion GlucoShot is an over-the-counter glucose spray developed by Generex Biotechnology Corporation. It utilizes Generex's proprietary buccal drug delivery technology, allowing for rapid absorption of glucose through the inner lining of the mouth. Marketed and distributed by Merck S.A. de C.V. in Mexico, it is intended for the rapid management of blood glucose levels, particularly in the context of diabetes.

Brand names: Diabion GlucoShot
Other names: Glucose RapidSpray

Beyond the preview

Go deeper on Diabion GlucoShot.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Diabion GlucoShot.

Explore the full profile